PL3518933T3 - Metody leczenia mięśniaków macicy i endometriozy - Google Patents

Metody leczenia mięśniaków macicy i endometriozy

Info

Publication number: PL3518933T3
Authority: PL; Poland
Prior art keywords: endometriosis; methods; uterine fibroids; treating uterine; treating
Prior art date: 2016-09-30

Application number

PL17823018T

Other languages

English (en)

Other versions

PL3518933T5 (pl

Inventor

Brendan Mark JOHNSON

Lynn Seely

JR. Paul N. MUDD

Susan Wollowitz

Mark Hibberd

Masataka TANIMOTO

Vijaykumar Reddy RAJASEKHAR

Mayukh Vasant SUKHATME

Original Assignee

Myovant Sciences Gmbh

Takeda Pharmaceutical Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-09-30

Filing date

2017-09-29

Publication date

2022-06-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3518933(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-09-29 Application filed by Myovant Sciences Gmbh, Takeda Pharmaceutical Company Limited filed Critical Myovant Sciences Gmbh

2022-06-20 Publication of PL3518933T3 publication Critical patent/PL3518933T3/pl

2025-05-05 Publication of PL3518933T5 publication Critical patent/PL3518933T5/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Surgical Instruments (AREA)

PL17823018.1T 2016-09-30 2017-09-29 Metody leczenia mięśniaków macicy i endometriozy PL3518933T5 (pl)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201662402034P	2016-09-30	2016-09-30
US201662402150P	2016-09-30	2016-09-30
US201662402055P	2016-09-30	2016-09-30
US201762492839P	2017-05-01	2017-05-01
US201762528409P	2017-07-03	2017-07-03
PCT/EP2017/074907 WO2018060501A2 (en)	2016-09-30	2017-09-29	Methods of treating uterine fibroids and endometriosis
EP17823018.1A EP3518933B2 (en)	2016-09-30	2017-09-29	Methods of treating uterine fibroids and endometriosis

Publications (2)

Publication Number	Publication Date
PL3518933T3 true PL3518933T3 (pl)	2022-06-20
PL3518933T5 PL3518933T5 (pl)	2025-05-05

Family

ID=60915460

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL22162349.9T PL4094766T3 (pl)	2016-09-30	2017-09-29	Doustna kombinacja o ustalonej dawce i jej zastosowanie w leczeniu mięśniaków macicy i endometriozy
PL17823018.1T PL3518933T5 (pl)	2016-09-30	2017-09-29	Metody leczenia mięśniaków macicy i endometriozy

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL22162349.9T PL4094766T3 (pl)	2016-09-30	2017-09-29	Doustna kombinacja o ustalonej dawce i jej zastosowanie w leczeniu mięśniaków macicy i endometriozy

Country Status (24)

Country	Link
US (4)	US11033551B2 (pl)
EP (2)	EP4094766B1 (pl)
JP (1)	JP7043503B2 (pl)
CN (1)	CN110312512B (pl)
AU (2)	AU2017336363B2 (pl)
BR (1)	BR112019006227A2 (pl)
CA (1)	CA3038879A1 (pl)
CY (1)	CY1125254T1 (pl)
DK (1)	DK3518933T4 (pl)
ES (2)	ES3018413T3 (pl)
FI (1)	FI3518933T4 (pl)
HR (1)	HRP20220708T4 (pl)
HU (2)	HUE059101T2 (pl)
IL (2)	IL265700B2 (pl)
LT (1)	LT3518933T (pl)
MD (1)	MD3518933T4 (pl)
MX (1)	MX2019003726A (pl)
NZ (1)	NZ752916A (pl)
PL (2)	PL4094766T3 (pl)
PT (1)	PT3518933T (pl)
RS (1)	RS63300B2 (pl)
SI (1)	SI3518933T2 (pl)
SM (1)	SMT202200254T1 (pl)
WO (1)	WO2018060501A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7043503B2 (ja)	2016-09-30	2022-03-29	ミオバントサイエンシズゲーエムベーハー	子宮筋腫及び子宮内膜症を治療する方法
AU2017334035B2 (en)	2016-09-30	2022-11-24	Sumitomo Pharma Switzerland Gmbh	Treatment of prostate cancer
CA3066190A1 (en)	2017-06-05	2018-12-13	ObsEva S.A.	Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
US11759464B2 (en)	2017-06-05	2023-09-19	Kissei Pharmaceutical Co., Ltd.	Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
AU2018419533A1 (en)	2018-04-19	2020-11-12	Abbvie Inc.	Methods of treating heavy menstrual bleeding
AU2019373349B2 (en) *	2018-10-29	2025-01-09	Kissei Pharmaceutical Co., Ltd.	Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
RU2711658C1 (ru) *	2019-04-16	2020-01-20	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта"	Способ лечения наружного генитального эндометриоза
CN110194776B (zh) *	2019-06-27	2021-05-28	四川伊诺达博医药科技有限公司	一种瑞卢戈利的合成方法
US20220305017A1 (en) *	2019-08-08	2022-09-29	ObsEva S.A.	Compositions and methods for the treatment of estrogen-dependent disorders
CN115175912B (zh) *	2019-10-10	2025-04-11	住友制药瑞士有限公司	N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式
CN115279769A (zh) *	2019-10-10	2022-11-01	梦欧文科学有限责任公司	N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
BR112022016625A2 (pt) *	2020-02-19	2022-11-16	Aspira Womens Health Inc	Composições para avaliação de endometriose tendo especificidade melhorada
CN113384581B (zh) *	2020-03-12	2023-11-14	成都倍特药业股份有限公司	一种包含促性腺激素释放激素拮抗剂的药物组合物
CA3185151A1 (en) *	2020-05-29	2021-12-02	Myovant Sciences Gmbh	Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
WO2022101303A1 (en)	2020-11-11	2022-05-19	Myovant Sciences Gmbh	Methods of administering relugolix
WO2023066941A1 (en)	2021-10-18	2023-04-27	Myovant Sciences Gmbh	Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN117069735A (zh) *	2022-05-10	2023-11-17	北京海美源医药科技有限公司	一种高效合成瑞卢戈利的方法和其应用
WO2024015934A2 (en) *	2022-07-13	2024-01-18	Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods of diagnostic screening and early detection of adenomyosis
WO2024102620A2 (en) *	2022-11-09	2024-05-16	Tempest Therapeutics, Inc.	Triazolone compounds and uses thereof
WO2025106820A1 (en) *	2023-11-16	2025-05-22	University Of South Florida	Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US402055A (en)		1889-04-23		Water-motor
US492839A (en)		1893-03-07		Key for brake-shoes
US528409A (en)		1894-10-30		Denis ahern
US402150A (en)		1889-04-30		Broadcast seed-sower
US402034A (en)		1889-04-23		Dumping-wagon
FR2512732A1 (fr)	1981-09-14	1983-03-18	Raffinage Cie Francaise	Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en)	1991-04-12	1994-08-23	University Of Southern California	Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es)	1996-01-11	1997-06-27		Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es)	1997-01-15	1998-04-07		Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de)	1998-04-03	1999-10-14	Jenapharm Gmbh	Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) *	1998-08-07	2001-07-24	Heinrichs William Leroy	Prevention of endometriosis signs or symptons
RU2233284C2 (ru)	1999-03-24	2004-07-27	Такеда Кемикал Индастриз, Лтд.	Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
TWI225863B (en)	1999-03-24	2005-01-01	Takeda Chemical Industries Ltd	Thienopyrimidine compounds, their production and use
EP1266898A4 (en)	2000-02-29	2003-05-21	Takeda Chemical Industries Ltd	PROCESSES FOR PRODUCING THIENOPYRAMIDINE DERIVATIVES
WO2003064429A1 (en)	2002-01-30	2003-08-07	Takeda Chemical Industries, Ltd.	Thienopyrimidines, process for preparing the same and use thereof
KR101074462B1 (ko)	2003-01-29	2011-10-18	다케다 야쿠힌 고교 가부시키가이샤	티에노피리미딘 화합물 및 그 용도
EP1646389B1 (en)	2003-07-07	2008-09-10	Neurocrine Biosciences, Inc.	Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
MY151322A (en)	2004-04-30	2014-05-15	Bayer Ip Gmbh	Management of breakthrough bleeding in extended hormonal contraceptive regimens
CA2615795C (en)	2005-07-22	2013-05-28	Takeda Pharmaceutical Company Limited	Premature ovulation preventive agent
AR058584A1 (es)	2005-12-22	2008-02-13	Takeda Pharmaceutical	Derivados de metastina y uso de los mismos
AR065948A1 (es)	2007-04-06	2009-07-15	Neurocrine Biosciences Inc	Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
WO2009062087A1 (en)	2007-11-07	2009-05-14	Neurocrine Biosciences, Inc.	Processes for the preparation of uracil derivatives
EP2329823A4 (en)	2008-09-03	2013-04-03	Takeda Pharmaceutical	PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
US9427418B2 (en)	2009-02-23	2016-08-30	Gtx, Inc.	Estrogen receptor ligands and methods of use thereof
US9624161B2 (en)	2009-02-23	2017-04-18	Gtx, Inc.	Estrogen receptor ligands and methods of use thereof
KR20140089402A (ko)	2010-06-16	2014-07-14	앙도르쉐르슈 인코포레이티드	에스트로겐-관련 질병의 치료 또는 예방 방법
JP2012077020A (ja)	2010-09-30	2012-04-19	Mochida Pharmaceut Co Ltd	ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
CN113372358B (zh)	2012-09-28	2024-05-14	武田药品工业株式会社	噻吩并嘧啶衍生物的制备方法
EP3384930A1 (en) *	2013-03-15	2018-10-10	AbbVie Inc.	Compositions for use in treating heavy menstrual bleeding
SI4233847T1 (sl)	2015-02-26	2025-02-28	Takeda Pharmaceutical Company Limited	Tableta, ki vsebuje derivat metoksiuree in delce manitola
CA3002791A1 (en)	2015-09-01	2017-03-09	Abbvie Inc.	Methods of administering elagolix
AU2017334035B2 (en)	2016-09-30	2022-11-24	Sumitomo Pharma Switzerland Gmbh	Treatment of prostate cancer
JP7043503B2 (ja)	2016-09-30	2022-03-29	ミオバントサイエンシズゲーエムベーハー	子宮筋腫及び子宮内膜症を治療する方法
CA3066190A1 (en)	2017-06-05	2018-12-13	ObsEva S.A.	Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
CN115279769A (zh)	2019-10-10	2022-11-01	梦欧文科学有限责任公司	N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
CN115175912B (zh)	2019-10-10	2025-04-11	住友制药瑞士有限公司	N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式
CA3185151A1 (en)	2020-05-29	2021-12-02	Myovant Sciences Gmbh	Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
WO2022101303A1 (en)	2020-11-11	2022-05-19	Myovant Sciences Gmbh	Methods of administering relugolix
WO2023066941A1 (en)	2021-10-18	2023-04-27	Myovant Sciences Gmbh	Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

2017
- 2017-09-29 JP JP2019538721A patent/JP7043503B2/ja active Active
- 2017-09-29 AU AU2017336363A patent/AU2017336363B2/en active Active
- 2017-09-29 BR BR112019006227-0A patent/BR112019006227A2/pt unknown
- 2017-09-29 MD MDE20190880T patent/MD3518933T4/ro unknown
- 2017-09-29 HU HUE17823018A patent/HUE059101T2/hu unknown
- 2017-09-29 SM SM20220254T patent/SMT202200254T1/it unknown
- 2017-09-29 PL PL22162349.9T patent/PL4094766T3/pl unknown
- 2017-09-29 CN CN201780072987.XA patent/CN110312512B/zh active Active
- 2017-09-29 MX MX2019003726A patent/MX2019003726A/es unknown
- 2017-09-29 EP EP22162349.9A patent/EP4094766B1/en active Active
- 2017-09-29 DK DK17823018.1T patent/DK3518933T4/da active
- 2017-09-29 HU HUE22162349A patent/HUE072130T2/hu unknown
- 2017-09-29 SI SI201731123T patent/SI3518933T2/sl unknown
- 2017-09-29 LT LTEPPCT/EP2017/074907T patent/LT3518933T/lt unknown
- 2017-09-29 HR HRP20220708TT patent/HRP20220708T4/hr unknown
- 2017-09-29 WO PCT/EP2017/074907 patent/WO2018060501A2/en not_active Ceased
- 2017-09-29 ES ES22162349T patent/ES3018413T3/es active Active
- 2017-09-29 NZ NZ752916A patent/NZ752916A/en unknown
- 2017-09-29 PL PL17823018.1T patent/PL3518933T5/pl unknown
- 2017-09-29 RS RS20220565A patent/RS63300B2/sr unknown
- 2017-09-29 PT PT178230181T patent/PT3518933T/pt unknown
- 2017-09-29 FI FIEP17823018.1T patent/FI3518933T4/fi active
- 2017-09-29 ES ES17823018T patent/ES2912929T5/es active Active
- 2017-09-29 CA CA3038879A patent/CA3038879A1/en active Pending
- 2017-09-29 EP EP17823018.1A patent/EP3518933B2/en active Active
2019
- 2019-03-28 IL IL265700A patent/IL265700B2/en unknown
- 2019-03-29 US US16/370,299 patent/US11033551B2/en active Active
2021
- 2021-05-11 US US17/317,769 patent/US11793812B2/en active Active
2022
- 2022-06-02 CY CY20221100390T patent/CY1125254T1/el unknown
- 2022-07-15 US US17/866,201 patent/US11957684B2/en active Active
- 2022-09-30 AU AU2022241582A patent/AU2022241582C1/en active Active
2023
- 2023-02-12 IL IL300580A patent/IL300580B2/en unknown
2024
- 2024-01-30 US US18/427,579 patent/US20240165118A1/en active Pending

Also Published As

Publication number	Publication date
CY1125254T1 (el)	2024-02-16
HUE059101T2 (hu)	2022-10-28
EP3518933B2 (en)	2025-02-26
PT3518933T (pt)	2022-05-10
EP4094766A1 (en)	2022-11-30
CN110312512B (zh)	2023-05-09
IL265700B1 (en)	2023-03-01
EP3518933A2 (en)	2019-08-07
US20240165118A1 (en)	2024-05-23
ES3018413T3 (es)	2025-05-16
US20210401841A1 (en)	2021-12-30
SI3518933T2 (sl)	2025-05-30
DK3518933T3 (da)	2022-05-30
JP2019529575A (ja)	2019-10-17
FI3518933T4 (fi)	2025-05-14
IL265700A (en)	2019-05-30
AU2017336363B2 (en)	2022-08-04
NZ752916A (en)	2022-09-30
RS63300B2 (sr)	2025-05-30
WO2018060501A2 (en)	2018-04-05
PL4094766T3 (pl)	2025-07-28
PL3518933T5 (pl)	2025-05-05
HUE072130T2 (hu)	2025-10-28
US11957684B2 (en)	2024-04-16
MX2019003726A (es)	2019-09-26
LT3518933T (lt)	2022-06-10
AU2017336363A1 (en)	2019-05-16
SMT202200254T1 (it)	2022-07-21
HRP20220708T4 (hr)	2025-04-25
CA3038879A1 (en)	2018-04-05
IL300580A (en)	2023-04-01
IL300580B1 (en)	2025-07-01
MD3518933T4 (ro)	2025-10-31
JP7043503B2 (ja)	2022-03-29
SI3518933T1 (sl)	2022-06-30
AU2022241582A1 (en)	2022-10-27
IL265700B2 (en)	2023-07-01
US11033551B2 (en)	2021-06-15
AU2022241582C1 (en)	2024-11-28
EP3518933B1 (en)	2022-03-16
BR112019006227A2 (pt)	2019-06-18
WO2018060501A3 (en)	2018-05-11
US20220370462A1 (en)	2022-11-24
RS63300B1 (sr)	2022-07-29
HRP20220708T1 (hr)	2022-07-22
ES2912929T5 (en)	2025-05-09
DK3518933T4 (da)	2025-04-22
ES2912929T3 (es)	2022-05-30
EP4094766B1 (en)	2025-04-02
US20190262346A1 (en)	2019-08-29
CN110312512A (zh)	2019-10-08
MD3518933T2 (ro)	2022-07-31
US11793812B2 (en)	2023-10-24
IL300580B2 (en)	2025-11-01
AU2022241582B2 (en)	2024-06-13

Publication	Publication Date	Title
IL300580B2 (en)	2025-11-01	Methods for treating uterine fibroids and endometrial disease
SG11201803619VA (en)	2018-05-30	Three-dimensional memory apparatuses and methods of use
GB2531863B (en)	2017-09-13	Security device and method of manufacture thereof
IL272570A (en)	2020-03-31	Methods and preparations for the detection and treatment of endometriosis
IL265359A (en)	2019-05-30	Modified Oligonucleotides and Methods of Use
GB201510073D0 (en)	2015-07-22	Security devices and methods of manufacture thereof
ZA201802902B (en)	2019-07-31	Methods and apparatuses for configuration of measurement restrictions
GB201417048D0 (en)	2014-11-12	Occupancy-control device and methods of use
IL252726A0 (en)	2017-08-31	Uterine clamps to treat postpartum bleeding and to help restore the uterus
SG10201405193QA (en)	2015-12-30	Hair extension device and related methods of manufacture
GB201620675D0 (en)	2017-01-18	Photociode device and method of manufacture
IL259096A (en)	2018-06-28	Peptides and methods of treating endometriosis using the same
GB201504838D0 (en)	2015-05-06	Security device and method of manufacture
GB2566975B (en)	2020-03-25	Security Device And Method Of Manufacture Thereof
PL3220908T3 (pl)	2022-11-07	Kompozycje i sposoby leczenia endometriozy
GB2526531B (en)	2017-08-30	Security device components and methods of manufacture thereof
SG10201702547QA (en)	2017-11-29	Methods of vibro-treating and vibro-treating apparatus
IL274190A (en)	2020-06-30	Methods for treating ischemic disease
IL248381A0 (en)	2016-11-30	A combination of brexpiprazole and nalemapine and its use in the treatment of drug-related disorders
IL246637A0 (en)	2016-08-31	Preparations and methods for the treatment of intracerebral hemorrhage
PL3328529T3 (pl)	2020-01-31	Urządzenie do mieszania masy formierskiej i sposób mieszania masy formierskiej
GB2527908B (en)	2021-06-09	Closure means and method of use thereof
HK40012837A (en)	2020-07-31	Methods of treating uterine fibroids and endometriosis
GB2556880B (en)	2020-06-10	Security device components and methods of manufacture thereof
GB201600264D0 (en)	2016-02-24	Fixation device location and method of manufacture and use